Mission

Open positions (pre and postdoctoral; mail to: procureico at gmail.com)

The Catalan Institute of Oncology (ICO) is a public center working exclusively in the field of cancer. Its approach to the disease is comprehensive, combining, all in one organization, prevention, care, specialized training and research. The ICO was founded in 1996 and has become a center of reference in Catalonia, both in healthcare quality and in research (top Spanish hospital-institute in terms of scientific impact). The Pujana's research group is part of the newly created ICO ProCURE research program, aimed at addressing a major clinical problem in oncology; the existence or emergence of cancer therapeutic resistance. The group is located in the Bellvitge Institute for Biomedical Research (IDIBELL) campus.

grup 2016 2

Selected publications

2016. Cancer network activity associated with therapeutic response and synergism. Genome Medicine 24;8(1):88.

2015. Integrating germline and somatic data towards a personalized cancer medicine. Trends Molecular Medicine 20(8):413-5.

2011. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biology Nov;9(11):e1001199.

2010. Biological reprogramming in acquired resistance to endocrine treatment of breast cancer. Oncogene 29(45):6071-83.

2007. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nature Genetics 39(11):1338-49.